References

The new paradigm of psychiatry precision medicine and its emerging clinical framework.

10.1192/j.eurpsy.2024.1389 · 2024 · External reference

Pharmacogenetic studies of drug response in schizophrenia.

10.1080/23808993.2016.1140554 · 2016 · External reference

A rating scale for drug-induced akathisia.

10.1192/bjp.154.5.672 · 1989 · External reference

Early-onset dystonia, exacerbation with fever, and striatal signal changes: emerging phenotype of DYT-PRKRA.

10.1212/wnl.0000000000200858 · 2022 · External reference

Mutation in Prkra results in cerebellar abnormality and reduced eIF2α phosphorylation in a model of DYT-PRKRA.

10.1242/dmm.050929 · 2024 · External reference

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

10.1016/s0140-6736(13)60733-3 · 2013 · External reference

PRKRAP1 and other pseudogenes in movement disorders: the troublemakers in genetic analyses are more than genomic fossils.

10.1002/mdc3.13499 · 2022 · External reference

PRKRA-related disorders: bilateral striatal degeneration in addition to DYT16 spectrum.

10.1002/mds.28492 · 2021 · External reference

The adenosine hypothesis of schizophrenia into its third decade: from neurochemical imbalance to early life etiological risks.

10.3389/fncel.2023.1120532 · 2023 · External reference

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

10.2147/tcrm.s117321 · 2017 · External reference

Management of common adverse effects of antipsychotic medications.

10.1002/wps.20567 · 2018 · External reference

Tardive dyskinesia and dystonia – clinical case review and grand rounds.

10.4103/jopsys.jopsys_24_22 · 2022 · External reference

Is allopurinol a marvel in the endgame of ultra-resistant schizophrenia?

10.1016/j.schres.2022.01.009 · 2022 · External reference

The dual advantage of allopurinol in a patient with severe mania and gout.

2024 · External reference